- Home
- WF vs VTRS Comparison
WF vs VTRS Comparison
Compare WF & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- VTRS
- Stock Information
- Founded
- WF 1899
- VTRS 1961
- Country
- WF South Korea
- VTRS United States
- Employees
- WF N/A
- VTRS N/A
- Industry
- WF Commercial Banks
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- WF Finance
- VTRS Health Care
- Exchange
- WF Nasdaq
- VTRS Nasdaq
- Market Cap
- WF 10.2B
- VTRS 10.6B
- IPO Year
- WF N/A
- VTRS N/A
- Fundamental
- Price
- WF $57.71
- VTRS $9.14
- Analyst Decision
- WF
- VTRS Hold
- Analyst Count
- WF 0
- VTRS 5
- Target Price
- WF N/A
- VTRS $10.40
- AVG Volume (30 Days)
- WF 74.4K
- VTRS 10.3M
- Earning Date
- WF 07-24-2025
- VTRS 08-07-2025
- Dividend Yield
- WF 3.65%
- VTRS 5.27%
- EPS Growth
- WF 19.20
- VTRS N/A
- EPS
- WF 2.49
- VTRS N/A
- Revenue
- WF $7,562,040,413.00
- VTRS $14,330,200,000.00
- Revenue This Year
- WF N/A
- VTRS N/A
- Revenue Next Year
- WF $2.09
- VTRS $1.85
- P/E Ratio
- WF $7.69
- VTRS N/A
- Revenue Growth
- WF 14.16
- VTRS N/A
- 52 Week Low
- WF $29.44
- VTRS $6.85
- 52 Week High
- WF $57.97
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- WF 87.15
- VTRS 54.56
- Support Level
- WF $49.20
- VTRS $9.03
- Resistance Level
- WF $55.06
- VTRS $9.39
- Average True Range (ATR)
- WF 0.87
- VTRS 0.21
- MACD
- WF 0.56
- VTRS -0.01
- Stochastic Oscillator
- WF 97.44
- VTRS 51.72
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.